Last Updated: 10 Nov 2024
Executive Summary
Charles River Laboratories (CRL) is a leading provider of preclinical and clinical laboratory services to the pharmaceutical, medical device, and biotechnology industries. The company has a strong financial position with a market capitalization of $11.01 billion, EBITDA of $948.77 million, and EPS of $8.01. CRL's stock price is currently trading at $215.39, which is below its 52-week high of $275. The company has a strong analyst rating, with 3 strong buy ratings, 4 buy ratings, and 13 hold ratings. The analyst target price is $216.48, which implies a potential upside of 0.5%.
Company Overview
Charles River Laboratories is an American pharmaceutical company that specializes in a variety of preclinical and clinical laboratory, gene therapy, and cell therapy services. The company also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offers support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing. CRL has a global presence with operations in over 20 countries.
Fundamental Analysis
CRL's financial performance has been strong in recent years. The company has reported positive revenue and earnings growth over the past several quarters. In the most recent quarter, CRL reported revenue of $4.06 billion, an increase of 0.016% year-over-year. The company also reported diluted EPS of $8.01, a decrease of 0.213% year-over-year. CRL's profit margin is 10.4%, and its operating margin is 14.7%. The company has a strong balance sheet with $1.46 billion in cash and equivalents and $2.26 billion in debt.
Technical Analysis
CRL's stock price has been trending lower in recent months. The stock is currently trading below its 50-day and 200-day moving averages. The relative strength index (RSI) is 45.6, which is in neutral territory. The moving average convergence divergence (MACD) indicator is also in neutral territory.
Short Term Outlook
The technical analysis suggests that CRL's stock price could continue to trend lower in the short term. The stock is trading below its moving averages and the RSI is in neutral territory. The MACD indicator is also in neutral territory. However, the analyst rating is strong, which suggests that the stock could rebound in the near term.
Long Term Outlook
The long-term outlook for CRL is positive. The company is a leader in the preclinical and clinical laboratory services industry. The company has a strong financial position and a global presence. CRL is well-positioned to continue to grow in the future.
Analyst Recommendations
The majority of analysts have a buy rating on CRL. The average analyst target price is $216.48, which implies a potential upside of 0.5%.
